Answers are grounded in this paper and cite their sources.
Diagnostic study demonstrates high agreement between handheld and laboratory TBI biomarker tests in blunt head trauma patients, indicating clinical interchangeability to rule out intracranial lesions.
BACKGROUND: Glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) are cleared by the U.S. Food and Drug Administration (FDA) to aid computed tomography (CT) decision-making in patients with traumatic brain injury (TBI). Two commercial assays, i-STAT TBI Plasma test and Alinity i TBI test, quantify these biomarkers using distinct detection technologies. Limited comparative data exist, creating uncertainty about cross-platform agreement and interchangeability of results in clinical and research applications. METHODS: GFAP and UCH-L1 concentrations were measured twice from 829 adults who underwent brain CT within 24 h of blunt trauma, first using the Abbott i-STAT TBI Plasma test and second using the Alinity i TBI test. Agreement was assessed using percent agreement (binary outcomes), Bland-Altman plots, Passing-Bablok regression, and Pearson correlation, with and without imputed values for out-of-range results. Diagnostic accuracy for traumatic intracranial lesions (tICLs) was calculated at assay-specific cutoffs. RESULTS: For GFAP + UCH-L1 in combination, the overall cross-platform agreement was 92.28%. GFAP and UCH-L1 showed strong cross-platform correlations with imputed (r = 0.916 and 0.916, respectively) and non-imputed data (r = 0.942 and 0.909, respectively). Both tests detected all clinically significant tICLs, with sensitivities of 100% (95% CI, 89%-100%) and negative predictive value (NPV) of 100% (95% CI, 98%-100%). Specificities were 29% (95% CI, 26%-32%) for i-STAT and 25% (95% CI, 22%-28%) for Alinity i. CONCLUSIONS: GFAP and UCH-L1 showed strong cross-platform agreement, individually and in combination, with equivalent sensitivity for tICL, supporting clinical interchangeability of the binary positive/negative test results.
No takes yet. Share an insight, caveat, or question.
Roberts et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: